Evidence map›Paper›PMID 25370185›Full record

Trial reportTrials2014

The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial.

Christopher G Davey, Andrew M Chanen, Sue M Cotton, Sarah E Hetrick, Melissa J Kerr, Michael Berk, Olivia M Dean, Kally Yuen, Mark Phelan, Aswin Ratheesh and 8 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Right choice, right time: Evaluation of an online decision aid for youth depression.Health expectations : an international journal of public participation in health care and health policy · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Christopher G DaveyOrygen, The National Centre of Excellence in Youth Mental Health, 35 Poplar Road, Parkville, VIC 3052, Australia. c.davey@unimelb.edu.au.
Andrew M Chanen
Sue M Cotton
Sarah E Hetrick
Melissa J Kerr
Michael Berk
Olivia M Dean
Kally Yuen
Mark Phelan
Aswin Ratheesh
Miriam R Schäfer
G Paul Amminger
Alexandra G Parker
Danijela Piskulic
Susy Harrigan
Andrew J Mackinnon
Ben J Harrison
Patrick D McGorry

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of the Youth Depression Alleviation-Combined Treatment (YoDA-C) study is to determine whether antidepressant medication should be started as a first-line treatment for youth depression delivered concurrently with psychotherapy. Doubts about the use of medication have been raised by meta-analyses in which the efficacy and safety of antidepressants in young people have been questioned, and subsequent treatment guidelines for youth depression have provided only qualified support. METHODS/

designYoDA-C is a double-blind, randomised controlled trial funded by the Australian government's National Health and Medical Research Council. Participants between the ages of 15 and 25 years with moderate to severe major depressive disorder will be randomised to receive either (1) cognitive behavioural therapy (CBT) and fluoxetine or (2) CBT and placebo. The treatment duration will be 12 weeks, and follow-up will be conducted at 26 weeks. The primary outcome measure is change in the Montgomery-Åsberg Depression Rating Scale (MADRS) after 12 weeks of treatment. The MADRS will be administered at baseline and at weeks 4, 8, 12 and 26. Secondary outcome measures will address additional clinical outcomes, functioning, quality of life and safety.

trial registrationAustralian and New Zealand Clinical Trials Registry ID: ACTRN12612001281886 (registered on 11 December 2012).

Indexed as

Cognitive Behavioral TherapyResearch DesignAdolescentAdolescent BehaviorAdultAge FactorsAntidepressive Agents, Second-GenerationClinical ProtocolsCombined Modality TherapyDouble-Blind MethodFemaleFluoxetineHumansMajor Depressive DisorderMalePredictive Value of TestsAntidepressive Agents, Second-GenerationFluoxetineSelective Serotonin Reuptake Inhibitors

Identifiers

PMID25370185
PMCPMC4230740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.